亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.

医学 结直肠癌 肿瘤科 内科学 随机对照试验 阶段(地层学) 辅助治疗 循环肿瘤DNA 佐剂 总体生存率 癌症 古生物学 生物
作者
Jeanne Tie,Yuxuan Wang,Serigne Lo,Kamel Lahouel,Joshua D. Cohen,Rachel Wong,Jeremy Shapiro,S.J. Harris,Adnan Khattak,Matthew Burge,Margaret Lee,Marion Harris,Sue‐Anne McLachlan,Sumitra Ananda,Craig Underhill,Nickolas Papadopoulos,Cristian Tomasetti,Kenneth W. Kinzler,Bert Vogelstein,Peter Gibbs
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 108-108 被引量:11
标识
DOI:10.1200/jco.2024.42.16_suppl.108
摘要

108 Background: Previous results of the DYNAMIC study demonstrated that a ctDNA-guided approach versus standard management in stage II colon cancer (CC) reduced adjuvant chemotherapy (ACT) use without compromising 2-year recurrence-free survival (RFS). MMR status defines two distinct subsets of stage II CC. Here, we report the impact of ctDNA burden, end of ACT (EOT) ctDNA, and updated survival data including overall survival (OS). Methods: DYNAMIC is a multi-center randomized phase II trial. Eligible patients (pts) had resected stage II CC and were suitable for ACT. Pts were randomly assigned 2:1 to ctDNA-guided management or standard management (clinician-guided based on conventional criteria). For ctDNA-guided management, a ctDNA-positive result at 4 or 7 weeks after surgery with a tumor-informed assay prompted oxaliplatin-based or fluoropyrimidine ACT; ctDNA-negative pts were not treated. Between Aug 2015 and Aug 2019, 302 received ctDNA-guided and 153 standard management. The primary endpoint was RFS, with a non-inferiority margin of 8.5%. Pre-specified key secondary endpoints were ACT use and OS, with an additional secondary endpoint of ctDNA clearance rate. Results: With a median follow-up of 59.6 months (IQR 55.0–61.5), 5-year RFS were 88% and 87% with ctDNA-guided and standard management, respectively (difference 1.1%, 95% confidence interval, -5.8% to 8.0%). 5-year OS for ctDNA-guided treatment was 93.8% and standard management 93.3% (HR 1.05; 95% CI, 0.47 to 2.37; P = 0.887). 5-year OS was significantly worse in treated ctDNA-positive versus untreated ctDNA-negative pts (85.6% vs 95.3%, HR 3.30; 95% CI, 1.02 to 9.05; P = 0.014). The 5-year OS for ctDNA-negative T3 and T4 disease were 96.0% and 90.6%, respectively (HR 2.45; 95% CI, 0.65 to 9.25; P = 0.171). For treated ctDNA-positive pts, ctDNA clearance was observed at EOT in 35/40 (87.5%). The 5-year RFS for EOT ctDNA clearance vs ctDNA persistence were 85.2% and 20.0%, respectively (HR 15.4; 95% CI, 3.91 to 61.0; P < 0.001). Pts with ≥ 0.38 (the median) mutant tumor molecules (MTM/mL) had a lower ctDNA clearance rate and worse RFS than pts with < 0.38 MTM/mL (ctDNA clearance 75% vs 100%, P = 0.047; 5-year RFS 58.9% vs 95.2%, HR 10.62, P = 0.005). Post-op ctDNA was detected in 5/59 (8.5%) of dMMR and 40/235 (17%) of pMMR cases. In an exploratory analysis, ctDNA clearance was observed in 3/4 (75%) and 32/36 (89%) of dMMR and pMMR cases, respectively. Conclusions: Mature outcome data confirms the previous finding of non-inferiority of RFS with a ctDNA-guided approach to ACT for stage II CC. For ctDNA-positive pts, the post-surgery mutation burden provides additional prognostic information, as does the EOT ctDNA result. Additional data is needed to define any differential impact of ACT by MMR status. This data supports a role for ctDNA analysis, including serial sampling, in the management of stage II CC. Clinical trial information: ACTRN12615000381583 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苹果完成签到 ,获得积分10
3秒前
殷勤的半凡完成签到,获得积分10
24秒前
耍酷的手套完成签到,获得积分10
28秒前
34秒前
39秒前
充电宝的应助被爱学习的doge采纳,获得10
39秒前
39秒前
39秒前
39秒前
orixero的应助被爱学习的doge采纳,获得10
39秒前
隐形曼青的应助被爱学习的doge采纳,获得10
39秒前
在水一方的应助被爱学习的doge采纳,获得10
39秒前
大模型的应助被爱学习的doge采纳,获得10
39秒前
华仔的应助被爱学习的doge采纳,获得10
39秒前
香蕉觅云的应助被爱学习的doge采纳,获得10
46秒前
CodeCraft的应助被爱学习的doge采纳,获得10
46秒前
SciGPT的应助被爱学习的doge采纳,获得10
46秒前
隐形曼青的应助被爱学习的doge采纳,获得10
46秒前
小二郎的应助被爱学习的doge采纳,获得10
46秒前
852的应助被爱学习的doge采纳,获得10
46秒前
46秒前
田様的应助被爱学习的doge采纳,获得10
46秒前
脑洞疼的应助被爱学习的doge采纳,获得10
47秒前
bkagyin的应助被爱学习的doge采纳,获得10
47秒前
顺利水桃完成签到,获得积分10
48秒前
51秒前
乐乐的应助被mengdewen采纳,获得10
57秒前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918